Abstract
Programmed cell death protein 1 pathway inhibitors are now routinely administered to patients with non-small cell lung cancer, and prompt recognition of immune-related adverse events is critical to managing serious drug toxicities. Here, we describe a 66-year-old man with no known history of diabetes who presented with diabetic ketoacidosis after receiving 3 doses of pembrolizumab for lung adenocarcinoma. Autoimmune diabetes is a rare but potentially life-threatening complication of programmed cell death protein 1 inhibitors.
MeSH terms
-
Aged
-
Antibodies, Monoclonal, Humanized / adverse effects
-
Antibodies, Monoclonal, Humanized / therapeutic use*
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use*
-
Autoantibodies / blood
-
Carcinoma, Non-Small-Cell Lung / complications
-
Carcinoma, Non-Small-Cell Lung / diagnosis*
-
Carcinoma, Non-Small-Cell Lung / drug therapy
-
Diabetic Ketoacidosis / diagnosis*
-
Diabetic Ketoacidosis / drug therapy
-
Diabetic Ketoacidosis / etiology
-
Drug-Related Side Effects and Adverse Reactions / diagnosis*
-
Glutamate Decarboxylase / immunology
-
Humans
-
Immunotherapy / adverse effects
-
Immunotherapy / methods*
-
Insulin / therapeutic use
-
Lung Neoplasms / complications
-
Lung Neoplasms / diagnosis*
-
Lung Neoplasms / drug therapy
-
Male
-
Programmed Cell Death 1 Receptor / immunology
-
Remission Induction
Substances
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents
-
Autoantibodies
-
Insulin
-
Programmed Cell Death 1 Receptor
-
pembrolizumab
-
Glutamate Decarboxylase
-
glutamate decarboxylase 2